Form 4: Assembly Biosciences Principal Accounting Officer Reports Stock Transactions

Jeanette M. Bjorkquist, Principal Accounting Officer of Assembly Biosciences, reports acquisition and disposal of company stock and stock options related to vesting and tax obligations.

Summary

• On March 29, 2024, Jeanette M. Bjorkquist, the Principal Accounting Officer of Assembly Biosciences, was granted 850 restricted stock units and 1,550 stock options.
• The restricted stock units vest in four approximately equal installments annually from March 29, 2025, to March 29, 2028.
• The stock options vest over four years, with 25% vesting on March 29, 2025, and the remaining 75% vesting in 36 approximately equal monthly installments, fully vesting on March 29, 2028.
• On April 1, 2024, Bjorkquist sold 114 shares of common stock at a weighted average price of $13.0719 per share, with prices ranging from $12.90 to $13.30.
• This sale was to cover tax withholding obligations related to the vesting and settlement of restricted stock units, as mandated by an administrative rule.
• Following these transactions, Bjorkquist directly owns 3,166 shares of Assembly Biosciences common stock and 1,550 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to equity compensation and tax obligations. There is no indication of significant positive or negative news.

Positives

• The grant of restricted stock units and stock options to a key officer aligns their interests with the long-term success of the company.
• The vesting schedules for both the restricted stock units and stock options encourage continued service and commitment from the officer.

Negatives

• The sale of shares, even if for tax obligations, could be perceived negatively by some investors, although it is mandated by company policy.

Risks

• Future fluctuations in the stock price could impact the value of the restricted stock units and stock options.
• Changes in the company's performance or outlook could affect the vesting of these equity awards.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Equity compensation practices, such as granting stock options and restricted stock units, are common in the biotechnology industry to attract and retain talent.
• Vesting schedules of four years are typical to incentivize long-term commitment.
• Sell-to-cover transactions for tax obligations are a standard practice to manage the tax implications of equity awards.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they involve a small number of shares.
• Employees who hold equity awards may be interested in the details of the vesting schedules and tax implications.

Key Dates